In This Article:
We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stands against the other stocks that are skyrocketing now.
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest. These stocks had a forgettable stretch over the past few years, but investors now see evidence that underperformance among mid-cap and small-cap names could end soon.
The S&P MidCap 400 and S&P 600 indexes still trail large caps by a wide margin, yet smaller firms have held up well even as interest rates remain elevated. The valuation gap between these groups and the biggest names in the market has also widened to levels that analysts consider unusually attractive.
Investors now expect momentum to build for select companies in this sweet spot, and many of them are in fast-growing industries with strong fundamentals.
Methodology
For this article, I screened the top-performing stocks year-to-date in the $1 billion to $5 billion market capitalization bracket. Stocks that I have covered this week will be excluded from this list.
I will also mention the number of hedge fund investors for these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A doctor presenting a new diagnostic test to a patient in an exam room.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Number of Hedge Fund Holders In Q3 2024: 19
Adaptive Biotechnologies (NASDAQ:ADPT) is a biotech company that makes immune medicine products. It focuses on Minimal Residual Disease (MRD) and Immune Medicine. The first is an FDA-cleared clonoSEQ test for cancer treatment response monitoring, and the second one uses immune receptor data for drug discovery and clinical trials.
The recent bullishness is due to the Centers for Medicare & Medicaid Services setting a favorable reimbursement rate of $2,007 for the company’s clonoSEQ test. It also announced a collaboration with NeoGenomics to expand access to MRD testing for blood cancer patients.
Adaptive also reported strong growth in its MRD business, with revenue growing 52% year-over-year in Q3 2024. The cost optimization focus also reduced its net loss by 36%.